4.8 Article

Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer

期刊

SCIENCE
卷 358, 期 6369, 页码 1443-+

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aal5240

关键词

-

资金

  1. NIH [R35 CA197568, R35 CA197735, K07 CA148894, R01 CA118553, R01 CA169141]
  2. Dana-Farber/Harvard Cancer Center GI SPORE P50 grant [CA 127003]
  3. American Cancer Society Research Professorship
  4. Hale Family Center for Pancreatic Cancer
  5. Project P Fund for Colorectal Cancer Research
  6. Stand-up-to Cancer (Colorectal Cancer Dream Team) the Chambers Family Fund for Colorectal Cancer Research
  7. Team Perry Fund
  8. Clark Family Fund for GI Cancer Research
  9. Prevent Cancer Foundation Figdor Family Fellowship
  10. Cellex Private Foundation
  11. Banco Bilbao Vizcaya Argentaria Foundation
  12. Eli Lilly Genentech
  13. Merck
  14. Sanofi
  15. Five Prime Therapeutics
  16. Merrimack Pharmaceuticals
  17. Bayer
  18. Agios Pharmaceuticals
  19. Lair Oncology
  20. KEW Group
  21. National Center for Biotechnology Information (NCBI) [PRINA362951]

向作者/读者索取更多资源

Colorectal cancers comprise a complex mixture of malignant cells, nontransformed cells, and microorganisms. Fusobacterium nucleatum is among the most prevalent bacterial species in colorectal cancer tissues. Here we show that colonization of human colorectal cancers with Fusobacterium and its associated microbiome-including Bacteroides, Selenomonas, and Prevotella species-is maintained in distal metastases, demonstrating microbiome stability between paired primary and metastatic tumors. In situ hybridization analysis revealed that Fusobacterium is predominantly associated with cancer cells in the metastatic lesions. Mouse xenografts of human primary colorectal adenocarcinomas were found to retain viable Fusobacterium and its associated microbiome through successive passages. Treatment of mice bearing a colon cancer xenograft with the antibiotic metronidazole reduced Fusobacterium load, cancer cell proliferation, and overall tumor growth. These observations argue for further investigation of antimicrobial interventions as a potential treatment for patients with Fusobacterium-associated colorectal cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据